Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/10718
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMacut D.-
dc.contributor.authorMladenovic, Violeta-
dc.contributor.authorBjekic-Macut J.-
dc.contributor.authorLivadas S.-
dc.contributor.authorStanojlovic O.-
dc.contributor.authorHrncic D.-
dc.contributor.authorRasic Markovic, Aleksandra-
dc.contributor.authorVojnović Milutinović, Danijela-
dc.contributor.authorAndric Z.-
dc.date.accessioned2021-04-20T16:28:51Z-
dc.date.available2021-04-20T16:28:51Z-
dc.date.issued2020-
dc.identifier.issn1573-4021-
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/10718-
dc.description.abstract© 2020 Bentham Science Publishers. Polycystic ovary syndrome (PCOS) is a common endocrine disease in women during reproductive age. It was shown that PCOS women are with high risk for dyslipidemia, glucose intolerance, type 2 diabetes and metabolic syndrome. These factors are considered to represent traditional risk factors for the occurrence of cardiovascular disease. Observed increased risk for hypertension in PCOS women seems to be associated with insulin resistance and hyperinsulinemia. Both conditions interfere with the endothelium-dependent vasodilatation mechanisms causing vascular muscle wall hypertrophy. Obesity and insulin resistance are considered key factors for the alteration of blood pressure in PCOS women. Higher cardiovascular risk is implicated in PCOS with aging and its consequent association with both systolic and diastolic blood pressure. The elements of renin-angiotensin-aldosterone system (RAAS) have an impact on endothelial dysfunction as a marker of cardiovascular damage that could be modified is women with PCOS. Androgens and components of RAAS are involved in the process of atherogenesis in PCOS women. Therefore, it is hypothesized that spironolactone treatment could ameliorate endothelial dysfunction in PCOS women. Recently it was shown that telmisartan, angiotensin II receptor antagonist poses insulin-sensitizing capacity to activate PPAR gamma and mediate favorable metabolic and reproductive effects in hypertensive PCOS women.-
dc.rightsrestrictedAccess-
dc.sourceCurrent Hypertension Reviews-
dc.titleHypertension in polycystic ovary syndrome: Novel insights-
dc.typereview-
dc.identifier.doi10.2174/1573402115666190531071422-
dc.identifier.scopus2-s2.0-85077025533-
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

136

Downloads(s)

6

Files in This Item:
File Description SizeFormat 
PaperMissing.pdf
  Restricted Access
29.86 kBAdobe PDFThumbnail
View/Open


Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.